Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant

AIMS: High dose melphalan (HDM) and autologous stem cell transplant (ASCT) is standard of care for multiple myeloma (MM), but there is significant variability in melphalan exposure (area under the plasma drug concentration–time curve, AUC) when using body surface area‐based dosing. Our aim was to es...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Clin Pharmacol
Main Authors: Sweiss, Karen, Vemu, Bhaskar, Hofmeister, Craig C., Wenzler, Eric, Calip, Gregory Sampang, Galvin, John P., Mahmud, Nadim, Rondelli, Damiano, Johnson, Jeremy James, Patel, Pritesh
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7576633/
https://ncbi.nlm.nih.gov/pubmed/32285957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14308
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares